Twenty-four-hour intragastric measurements in twenty healthy subjects: effect of enisoprost, a novel and potent antisecretory and antipeptic synthetic E1 prostaglandin.
Gastric aspiration was performed continuously overnight and at hourly intervals during the daytime in 20 healthy male volunteers. Medications used included enisoprost 100, 200 or 400 micrograms, misoprostol 200 micrograms and placebo, given at bedtime. Each dose of enisoprost markedly inhibited nocturnal mean acid output, hydrogen ion activity, pH and peptic activity. The duration of these effects was up to 10 h. Misoprostol, given at bedtime, also decreased acid secretion, but the effect was significantly less than that observed with any of the doses of enisoprost. A dose-response effect for enisoprost was found for the mean nocturnal hydrogen ion activity and pH, as well as for maximum pH attained. Although enisoprost, given at bedtime, had a marked inhibitory effect on acid and pepsin secretion for the overnight interval, this did not result in rebound hyperacidity or a rise in serum total gastrin concentration. The results of this study suggest that enisoprost should be tested by clinical trial for the treatment of peptic ulcer disease.
Thomson
A B
AB
Division of Gastroenterology, University of Alberta, Ontario, Canada.
McCullough
H N
HN
Kirdeikis
P
P
Zuk
L
L
Simpson
I
I
Cook
D J
DJ
Wildeman
R A
RA
Brunet
K
K
Fisher
D
D
Pinchbeck
B
B
D000293:Adolescent; D000328:Adult; D000527:Alprostadil / Q000031:analogs & derivatives* / Q000494:pharmacology; D000897:Anti-Ulcer Agents / Q000494:pharmacology*; D002940:Circadian Rhythm; D004311:Double-Blind Method; D005744:Gastric Acid / Q000378:metabolism*; D005745:Gastric Acidity Determination; D006801:Humans; D008297:Male; D010434:Pepsin A / Q000037:antagonists & inhibitors; D011465:Prostaglandins, Synthetic / Q000494:pharmacology*
D000897:Anti-Ulcer Agents; D011465:Prostaglandins, Synthetic; D010434:Pepsin A; D000527:Alprostadil; C054594:enisoprost